Travere Therapeutics, Inc. TVTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2003-07-23
Travere Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -88.8% | -78.3% | -48.7% | -34.7% | -43.6% |
| Net margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% | -38.6% | -35.9% |
| FCF margin | — | — | -224.5% | -238.5% | -61.7% | -25.0% | -33.3% | -15.6% | 4.2% | -3.6% |
| Return on assets | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% | -27.9% | -24.2% | -14.5% | -11.5% | -9.1% |
| Return on equity | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | -80.2% | -66.2% | -32.3% | -20.4% | -15.6% |
| Current ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 | 4.43 | 4.50 | 4.74 | 3.80 | 3.99 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.